Pausing methotrexate to boost pneumonia vaccine response
Treatments studied
Part of Bones, joints & muscles, Immune system & allergy clinical trials.
This study tests whether stopping methotrexate for a short time before getting the pneumonia vaccine (PCV20) helps your body build a stronger immune response. It is for people with autoimmune rheumatic diseases like rheumatoid arthritis or lupus whose disease is under control.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older with an autoimmune rheumatic disease (like rheumatoid arthritis, psoriatic arthritis, lupus, or others).
- You have been taking a stable dose of methotrexate for at least 12 weeks.
- You take no more than 5 mg of prednisone per day.
- Your disease is well-controlled (low activity or in remission).
- You have not already received the PCV20 pneumonia vaccine.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if a pneumonia vaccine (PCV20) is safe and works well in children and young adults with certain autoimmune rheumatic diseases like juvenile arthritis, lupus, or dermatomyositis. It aims to help protect them from serious infections.
This trial tests whether a preventive treatment can stop pneumocystis pneumonia (a lung infection) in people with autoimmune inflammatory rheumatic diseases who are taking steroids or other immune-suppressing medicines. It aims to find the safest and most effective way to protect you from this serious infection.
This study looks at how well methotrexate injections work in people with rheumatoid arthritis. It is designed for patients who are starting or changing to this type of methotrexate treatment.
This study tests a methotrexate injection (given under the skin) for people with moderate to severe rheumatoid arthritis who haven't taken methotrexate before. Researchers want to see how the medicine builds up in your body and if it helps control your symptoms.
This study tests whether increasing the dose of methotrexate or switching from pills to injections can better control rheumatoid arthritis symptoms. It aims to find the best way to use this common medication to reduce joint pain and swelling.
This Phase 3 study tests whether low-dose trimethoprim-sulfamethoxazole (also called TMP-SMX) can treat Pneumocystis pneumonia (PCP) in people with weakened immune systems. It may help improve treatment while reducing side effects compared with standard dosing.
Hear when a new Autoimmune Rheumatic Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.